share_log

Akanda To Supply Tetra Bio-Pharma With Cannabis For FDA Trials Of Cancer-Pain Drug

Akanda To Supply Tetra Bio-Pharma With Cannabis For FDA Trials Of Cancer-Pain Drug

Akanda将向Tetra Bio-Pharma提供大麻,用于美国食品药品管理局的癌症止痛药物试验
Benzinga Real-time News ·  2022/07/12 21:20

Akanda Corp. (NASDAQ:AKAN) will supply Tetra Bio-Pharma (OTCQB:TBPMF) (TSX:TBP) (FRA:JAM1) with pharmaceutical grade cannabis flower in a microdose cap form, for use in a Storz & Bickel Mighty Medic Vaporizer for global commercialization of Tetra's QIXLEEF and related products.

阿坎达公司 (纳斯达克股票代码:AKAN) 将供应利乐生物制药 (OTCQB: TBPMF) (TSX: TBP) (FRA: JAM1) 含药用级大麻花 采用微剂量瓶盖形式,用于 Storz & Bickel Mighty Medic Vaporizer 用于 Tetra 的全球商业化 QIXLEEF 和相关产品。

In addition, Akanda will act as a contract development and manufacturing organization (CDMO) for Tetra's clinical drug and commercial supply programs. With this project, Akanda becomes a CDMO in addition to being an EU GMP cannabis manufacturer, marking Akanda's first entry into cannabinoid drug development, which is a new and growing market opportunity for the company.

此外,阿坎达将充当c合同 d开发和 m制造 o组织 (CDMO)用于Tetra的临床药物和商业供应计划。通过这个项目,Akanda除了成为欧盟GMP大麻制造商外,还成为了CDMO,这标志着Akanda的第一个项目 进入大麻素药物开发,这对公司来说是一个新的和不断增长的市场机会。

QIXLEEF is a proprietary botanical inhaled investigational new drug currently being studied in two U.S. Food and Drug Administration authorized clinical trials: 1) REBORN 1, a Phase 2 study authorized by the FDA to evaluate inhaled cannabinoids against a class of immediate-release oral opioids for the management of breakthrough cancer pain, and 2) PLENITUDE, a Phase 2 multicenter clinical trial authorized by the FDA to evaluate the safety and efficacy of inhaled cannabinoids to relieve uncontrolled pain in patients with advanced cancer.

QIXLEEF是一种专有的植物吸入性在研新药,目前正在美国食品药品监督管理局的两项授权临床试验中进行研究:1) REBORN 1,这是一项由美国食品药品管理局授权的用于评估吸入大麻素与一类用于治疗突破性癌症疼痛的速释口服阿片类药物的2期多中心临床试验;2) PLENITUDE,一项由美国食品药品管理局授权的用于评估吸入大麻的安全性和有效性的2期多中心临床试验类药物可缓解晚期癌症患者不受控制的疼痛。

Under the multi-year agreement, Akanda will supply Tetra with quality, premium THC and CBD flower, and will provide regulatory, quality and pharmaceutical manufacturing services for the QIXLEEF clinical drug development and marketing authorization from its Portugal operations.

根据这项多年协议,Akanda将向Tetra提供优质、优质的四氢大麻酚和CBD花,并将为其葡萄牙业务的QIXLEEF临床药物开发和上市授权提供监管、质量和药品制造服务。

"This supply agreement with Tetra is a major milestone in Akanda's journey in becoming a cannabis platform company serving all regulated markets in the EMEA region," stated Tej Virk, CEO of Akanda. "In supporting a terrific partner with a mission to improve patient health and quality of life though cannabinoid-derived medicine, we are demonstrating that cannabis can fit into the traditional public sector model, with the expectation of reimbursement. Simultaneously, we are productively utilizing our diverse capabilities to support clinical trials for pharma grade cannabinoids. If approved, we expect to provide flower for the authorized compound, potentially creating a significant, incremental revenue stream for Akanda. This opportunity could only have been possible with our state-of-the-art facilities that we gained through the acquisition of Holigen in May."

他说:“与Tetra的供应协议是Akanda成为一家为欧洲、中东和非洲地区所有受监管市场提供服务的大麻平台公司历程中的一个重要里程碑。” Tej Virk,阿坎达首席执行官。“通过支持一个以通过大麻素衍生药物改善患者健康和生活质量为使命的优秀合作伙伴,我们证明大麻可以融入传统的公共部门模式,但有望获得报销。同时,我们正在富有成效地利用我们的多样化能力来支持制药级大麻素的临床试验。如果获得批准,我们预计将为授权化合物提供鲜花,这有可能为Akanda创造可观的增量收入来源。只有借助我们在五月份收购Holigen获得的最先进的设施,这个机会才有可能。”

Meet Akanda's CEO Tej Virk and a slew of other cannabis execs, entrepreneurs, CEOs, investors, etc. at the September Benzinga Cannabis Capital Conference, Sept. 13-14 in Chicago. Get your tickets HERE and reserve your spot at the Palmer House Hotel HERE.

遇见 阿坎达的 首席执行官 Tej Virk 9月13日至14日在芝加哥举行的9月Benzinga大麻资本会议上,还有许多其他大麻高管、企业家、首席执行官、投资者等。在这里获取门票,然后在这里预订帕尔默故居酒店的座位。

Photo: Courtesy of Business Wire

照片:由美国商业资讯提供

Related News

相关新闻

Akanda's CanMart Partners With Phlo Connect And Cellen Life Sciences To Strengthen Its Position In UK Medical Cannabis Market

Akanda的CanMart与Phlo Connect和Cellen Life Sciences合作巩固其在英国医用大麻市场的地位

The Flowr Corp. Revenue Grows 64% In 2021, Achieves Record Quarterly Revenue Thanks To This

Flowr Corp. 的收入在2021年增长了64%,因此实现了创纪录的季度收入

Halo Collective Q1 2022 Revenue Slightly Drops, Announces Significant Reductions

Halo Collective 2022 年第一季度收入略有下降,宣布大幅减少

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发